What Recursion does
Recursion (NASDAQ: RXRX) is a clinical-stage TechBio company developing an end-to-end, AI-native drug discovery and development platform it calls the Recursion OS. The company’s approach combines high-throughput automated laboratory experimentation with proprietary multimodal biological and chemical datasets and purpose-built machine learning models, then connects those “dry” and “wet” components in an iterative, lab-in-the-loop cycle intended to accelerate how programs move from target hypotheses through preclinical and clinical execution. Recursion operates across multiple therapeutic areas including oncology and rare disease, and it states that its OS is used to industrialize discovery and improve speed/efficiency versus traditional pharmaceutical R&D benchmarks.
Strategically, Recursion has been scaling its platform while moving a portfolio of wholly owned and partnered clinical programs toward clinical proof and translation. A major structural inflection was its completed combination with Exscientia, which Recursion characterizes as creating a vertically integrated, technology-enabled drug discovery platform with end-to-end capabilities. In executive leadership, Recursion announced that Najat Khan would succeed co-founder Chris Gibson as CEO and President effective January 1, 2026; Gibson transitioned to Chairman of the Board (with Recursion reporting subsequent board and leadership changes in 2025–2026).
Recursion’s platform is presented as modular and “bilingual” across science and AI, including dedicated internal AI and data components (e.g., Valence Labs) and model releases such as Boltz-2 (open-source) that Recursion frames as advancing predictive biology/chemistry modeling for drug discovery. The company also emphasizes ongoing partnership execution (e.g., Roche/Genentech collaboration work in neuroscience/oncology, and Genentech advancing an early discovery program in 2026), and it reports detailed cash/runway guidance in its quarterly results releases.